Press Releases

European Union patent applies to 38 member states with expiry extended to 2032 SOLANA BEACH, Calif. , April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European

First North American patent for Gimoti with expiry in 2032 SOLANA BEACH, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial

186 of 200 Subjects Enrolled in Phase 3 Clinical Trial of EVK-001

Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI SOLANA BEACH, Calif. , March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),   a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an

Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide SOLANA BEACH, Calif. , Oct.

Manufacturing Program Includes Three Year Registration Stability Data

Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize and support Gastroparesis Awareness Month through continued support of the International Foundation

“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” SOLANA BEACH, Calif. , and CHICAGO , July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study SOLANA BEACH , Calif., and CHICAGO , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused

Health care practitioners’   perception of nasal route of administration similar to IV;  92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas , October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO , Oct.